Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising
Hearing (House)
Summary
The bill changes Maryland’s corporate income tax by requiring companies that sponsor or own certain prescription drugs to include the amount they deducted federally for direct‑to‑consumer advertising in their Maryland taxable income. It applies to advertising aimed at the general public via broadcast, digital platforms, and similar media, but not ads in journals. The change takes effect for tax years beginning after Dec. 31, 2025.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HB 484
3 free questions a day, no accountHearings
- Ways and Means — Bill HearingWays and Means · Feb 12, 2026
History
- Hearing 2/12 at 1:00 p.m.
- First Reading Ways and Means
Sponsors
- Ziegler · sponsor
- Addison
- Charkoudian
- Cullison
- Ebersole
- Feldmark
- Guzzone
- Hill
- Moreno
- Terrasa
- Watson
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HB 484 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HB 484 freeOr ask your AI assistant about HB 484 directly:
Add to Claude, ChatGPT or Cursor